Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery

January 05, 2015
ALCHEMIST - A151216
Lung Cancer
Maria Quejada, MD

Naperville, Plainfield

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

Sponsor: Alliance for Clinical Trials in Oncology

https://clinicaltrials.gov/ct2/show/NCT02194738?term=alchemist&rank=2

  • Clinical stage IB , II or IIIA non-squamous non-small cell lung cancer, completely resected
  • No patients who have received neoadjuvant therapy (chemo- or radio-therapy)
  • No interstitial fibrosis or lung disease
  • No prior or concurrent malignancies within 5 years, except non-melanoma skin carcinoma or in situ carcinomas
  • Adequate formalin-fixed, paraffin-embedded (FFPE) tissue available for central EGFR and ALK genotyping for all patients, including those already identified to carry eligible 
  • EGFR or ALK alterations

5-6 years

Accepting Participants
Observational
Kathy Seymour, BSN
630-646-6050
630-646-6110
630-646-6075